Courtesy of Benzinga.
Synageva
BioPharma (NASDAQ: GEVA) today
announced that it met the enrollment target of 50 patients in ARISE (Acid
Lipase Replacement Investigating
Safety and Efficacy),
a global Phase 3 trial with sebelipase alfa in children and adults with
lysosomal acid lipase deficiency (LAL Deficiency). To accommodate
individuals still in the screening process, total enrollment will exceed
the planned number of 50 patients, with the final patient expected to be
randomized by the end of this year. As a result of today’s enrollment
update, the company expects to report top-line results from the ARISE
trial during the second half of 2014.
